Tags

Type your tag names separated by a space and hit enter

The Role of FGFR1 Gene Amplification as a Poor Prognostic Factor in Squamous Cell Lung Cancer: A Meta-Analysis of Published Data.
Biomed Res Int. 2015; 2015:763080.BR

Abstract

OBJECTIVES

The prognostic factors of the fibroblast growth factor receptor 1 (FGFR1) in non-small cell lung cancer (NSCLC) remain controversial.

METHODS

We conducted a meta-analysis of published studies from 1974 to February 2015. In absence of quality difference between studies of reporting significant and nonsignificant results, the relationship between FGFR1 amplification and clinicopathological parameters in NSCLC was analyzed. And also the combined hazard ratio (HR) and their corresponding 95% confidence interval (CI) were calculated in terms of overall survival.

RESULTS

3178 patients (12 studies) were included in the analysis. It was shown that FGFR1 amplification was significantly more prevalent among male patients (RR 2.03, 95% CI 1.57-2.63) with squamous cell lung cancer (SQCC) (RR 3.49, 95% CI 2.62-4.64) and current smokers (RR 2.63, 95% CI 1.92-3.60). The pooled data also showed that the FGFR1 amplification was a poor prognostic factor in SQCC (HR 1.38, 95% CI 1.07-1.78), Asian patients (HR 1.78, 95% CI 1.22-2.60), and fluorescence in situ hybridization (FISH) method (HR 1.30, 95% CI 1.06-1.58).

CONCLUSIONS

This meta-analysis strongly suggests that FGFR1 amplification occurs more frequently in male, SQCC and smokers, and it is a risk factor for poor prognosis among Asian patients with SQCC.

Authors+Show Affiliations

Division of Oncology, Nanjing Medical University, Nanjing 210000, China.Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210000, China.Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210000, China.College of Sciences, Nanjing University of Technology, Nanjing 210000, China.School of Public Health, Division of Biostatistics, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.Division of Oncology, Nanjing Medical University, Nanjing 210000, China.Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210000, China.Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210000, China.Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210000, China.Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210000, China.Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210000, China.

Pub Type(s)

Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26788508

Citation

Wang, Yang, et al. "The Role of FGFR1 Gene Amplification as a Poor Prognostic Factor in Squamous Cell Lung Cancer: a Meta-Analysis of Published Data." BioMed Research International, vol. 2015, 2015, p. 763080.
Wang Y, Gao W, Xu J, et al. The Role of FGFR1 Gene Amplification as a Poor Prognostic Factor in Squamous Cell Lung Cancer: A Meta-Analysis of Published Data. Biomed Res Int. 2015;2015:763080.
Wang, Y., Gao, W., Xu, J., Chen, X., Yang, Y., Zhu, Y., Yin, Y., Guo, R., Liu, P., Shu, Y., & Liu, L. (2015). The Role of FGFR1 Gene Amplification as a Poor Prognostic Factor in Squamous Cell Lung Cancer: A Meta-Analysis of Published Data. BioMed Research International, 2015, 763080. https://doi.org/10.1155/2015/763080
Wang Y, et al. The Role of FGFR1 Gene Amplification as a Poor Prognostic Factor in Squamous Cell Lung Cancer: a Meta-Analysis of Published Data. Biomed Res Int. 2015;2015:763080. PubMed PMID: 26788508.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The Role of FGFR1 Gene Amplification as a Poor Prognostic Factor in Squamous Cell Lung Cancer: A Meta-Analysis of Published Data. AU - Wang,Yang, AU - Gao,Wen, AU - Xu,Jiali, AU - Chen,Xiaojun, AU - Yang,Yang, AU - Zhu,Yizhi, AU - Yin,Yongmei, AU - Guo,Renhua, AU - Liu,Ping, AU - Shu,Yongqian, AU - Liu,Lingxiang, Y1 - 2015/12/16/ PY - 2015/08/08/received PY - 2015/09/30/accepted PY - 2016/1/21/entrez PY - 2016/1/21/pubmed PY - 2016/10/13/medline SP - 763080 EP - 763080 JF - BioMed research international JO - Biomed Res Int VL - 2015 N2 - OBJECTIVES: The prognostic factors of the fibroblast growth factor receptor 1 (FGFR1) in non-small cell lung cancer (NSCLC) remain controversial. METHODS: We conducted a meta-analysis of published studies from 1974 to February 2015. In absence of quality difference between studies of reporting significant and nonsignificant results, the relationship between FGFR1 amplification and clinicopathological parameters in NSCLC was analyzed. And also the combined hazard ratio (HR) and their corresponding 95% confidence interval (CI) were calculated in terms of overall survival. RESULTS: 3178 patients (12 studies) were included in the analysis. It was shown that FGFR1 amplification was significantly more prevalent among male patients (RR 2.03, 95% CI 1.57-2.63) with squamous cell lung cancer (SQCC) (RR 3.49, 95% CI 2.62-4.64) and current smokers (RR 2.63, 95% CI 1.92-3.60). The pooled data also showed that the FGFR1 amplification was a poor prognostic factor in SQCC (HR 1.38, 95% CI 1.07-1.78), Asian patients (HR 1.78, 95% CI 1.22-2.60), and fluorescence in situ hybridization (FISH) method (HR 1.30, 95% CI 1.06-1.58). CONCLUSIONS: This meta-analysis strongly suggests that FGFR1 amplification occurs more frequently in male, SQCC and smokers, and it is a risk factor for poor prognosis among Asian patients with SQCC. SN - 2314-6141 UR - https://www.unboundmedicine.com/medline/citation/26788508/The_Role_of_FGFR1_Gene_Amplification_as_a_Poor_Prognostic_Factor_in_Squamous_Cell_Lung_Cancer:_A_Meta_Analysis_of_Published_Data_ L2 - https://doi.org/10.1155/2015/763080 DB - PRIME DP - Unbound Medicine ER -